Abstract
Since conventional therapies are directly dependent on the supply of either drugs or oxygen, a key question is whether antiangiogenic agents produce detrimental effects on tumor vascular function, thus compromising combination therapies. A second question is whether experimental results based on fast-growing, transplanted tumors mimic those in slowly developing spontaneous tumors, which may be more representative of response in human primary tumors. To investigate changes in tumor pathophysiology, three antiangiogenic agents were compared: a) endostatin, b) anti-VEGFR-2 (DC101), and c) celecoxib. Total blood vessels were identified using anti-CD31, perfused vessels using DiOC7, and hypoxia by EF5 uptake. Although individual tumor growth rates varied substantially, DC101 produced the most striking inhibition. DC101 increased total and perfused vessel spacing as well as overall hypoxia, while endostatin increased total vessel spacing, and hypoxia and celecoxib had no marked effects. These results reinforce the idea that pathophysiological changes in spontaneous tumors are in general reflective of response in transplanted tumors. Furthermore, although DC101 inhibited growth in roughly half of the spontaneous tumors, the remaining tumors were unaffected. A key focus of future studies will be to investigate the underlying rationale for the widely varying antiangiogenic response among tumors that outwardly appear so similar.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
P. A. Burke, and S. J. DeNardo, Antiangiogenic agents and their promising potential in combined therapy, Crit. Rev. Oncol. Hematol. 39, 155–171 (2001).
J. C. Lee, D. C. Kim, M. S. Gee, H. M. Saunders, C. M. Sehgal, M. D. Feldman, S. R. Ross, and W. M. Lee, Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas, Cancer Res. 62, 747–755 (2002).
B. M. Fenton, S. F. Paoni, B. K. Beauchamp, B. Tran, L. Liang, B. Grimwood, and I. Ding, Evaluation of microregional variations in tumor hypoxia following the administration of endostatin, Adv. Exp. Med. Biol. 510, 19–24 (2003).
T. Boehm, J. Folkman, T. Browder, and M. S. O’Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance, Nature 390, 404–407 (1997).
C. J. Bruns, M. Shrader, M. T. Harbison, C. Portera, C. C. Solorzano, K. W. Jauch, D. J. Hicklin, R. Radinsky, and L. M. Ellis, Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice, Int. J. Cancer 102, 101–108 (2002).
Y. Izumi, E. di Tomaso, A. Hooper, P. Huang, J. Huber, D. J. Hicklin, D. Fukumura, R. K. Jain, and H. D. Suit, Responses to antiangiogenesis treatment of spontaneous autochthonous tumors and their isografts, Cancer Res. 63, 747–751 (2003).
K. M. Leahy, R. L. Ornberg, Y. Wang, B. S. Zweifel, A. T. Koki, and J. L. Masferrer, Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo, Cancer Res. 62, 625–631 (2002).
P. K. Lala, N. Al-Mutter, and A. Orucevic, Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HeJ mice, Int. J. Cancer 73, 371–380 (1997).
B. M. Fenton, S. F. Paoni, J. Lee, C. J. Koch, and E. M. Lord, Quantification of tumor vascular development and hypoxia by immunohistochemical staining and HbO2 saturation measurements, Br. J. Cancer 79, 464–471 (1999).
E. M. Lord, L. Harwell, and C. J. Koch, Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts, Cancer Res. 53, 5721–5726 (1993).
B. M. Fenton, S. F. Paoni, B. K. Beauchamp, and I. Ding, Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis, Br. J. Cancer 86, 1831–1836 (2002).
Y. Yokoyama, J. E. Green, V. P. Sukhatme, and S. Ramakrishnan, Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model, Cancer Res. 60, 4362–4365 (2000).
K. Boggio, E. Di Carlo, S. Rovero, F. Cavallo, E. Quaglino, P. L. Lollini, P. Nanni, G. Nicoletti, S. Wolf, P. Musiani, and G. Forni, Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice, Cancer Res. 60, 359–364 (2000).
G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest. 111, 1287–1295 (2003).
G. Bergers, K. Javaherian, K. M. Lo, J. Folkman, and D. Hanahan, Effects of angiogenesis inhibitors on multistage carcinogenesis in mice, Science 284, 808–812 (1999).
D. R. Sorensen, T. A. Read, T. Porwol, B. R. Olsen, R. Timpl, T. Sasaki, P. O. Iversen, H. B. Benestad, B. K. Sim, and R. Bjerkvig, Endostatin reduces vascularization, blood flow, and growth in a rat gliosarcoma, Neuro-oncol 4, 1–8 (2002).
B. M. Fenton, S. F. Paoni, B. G. Grimwood, and I. Ding, Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas, Int. J. Radial. Oncol. Biol. Phys. 57(4), 1038–1046 (2003).
N. N. Hanna, S. Seetharam, H. J. Mauceri, M. A. Beckett, N. T. Jaskowiak, R. M. Salloum, D. Hari, M. Dhanabal, R. Ramchandran, R. Kalluri, V. P. Sukhatme, D. W. Kufe, and R. R. Weichselbaum, Antitumor interaction of short-course endostatin and ionizing radiation, Cancer J. 6, 287–293 (2000).
M. Prewett, J. Huber, Y. W. Li, A. Santiago, W. O’Connor, K. King, J. Overholser, A. Hooper, B. Pytowski, L. Witte, P. Bohlen, and D. J. Hicklin, Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors, Cancer Res. 59, 5209–5218 (1999).
N. Hansen-Algenstaedt, B. R. Stall, T. P. Padera, D. E. J. G. Dolmans, D. J. Hicklin, D. Fukumura, and R. K. Jain, Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy, Cancer Res. 60, 4556–4560 (2000).
S. V. Kozin, Y. Boucher, D. J. Hicklin, P. Bohlen, R. K. Jain, and H. D. Suit, Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts, Cancer Res. 61, 39–44 (2001).
B. M. Fenton, B. K. Beauchamp, S. F. Paoni, P. Okunieff, and I. Ding, Characterization of the effects of antiangiogenic agents on tumor pathophysiology, Am. J. Clin. Oncol. 24, 453–457 (2001).
J. L. Masferrer, K. M. Leahy, A. T. Koki, B. S. Zweifel, S. L. Settle, B. M. Woerner, D. A. Edwards, A. G. Flickinger, R. J. Moore, and K. Seibert, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res. 60, 1306–1311 (2000).
W. Shi, C. Teschendorf, N. Muzyczka, and D. W. Siemann, Gene therapy delivery of endostatin enhances the treatment efficacy of radiation, Radiother. Oncol. 66, 1–9 (2003).
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Fenton, B.M., Paoni, S.F., Grimwood, B., Ding, I. (2005). Varied Response of Spontaneous Tumors to Antiangiogenic Agents. In: Okunieff, P., Williams, J., Chen, Y. (eds) Oxygen Transport to Tissue XXVI. Advances in Experimental Medicine and Biology, vol 566. Springer, Boston, MA. https://doi.org/10.1007/0-387-26206-7_9
Download citation
DOI: https://doi.org/10.1007/0-387-26206-7_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25062-5
Online ISBN: 978-0-387-26206-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)